晚期胃癌化疗中含铂类药物敏感性与切除修复交叉互补基因2和P53蛋白表达的相关性

Correlation between the expression of excision repair cross complementing 2 and P53 and platinum-based chemotherapy sensitivity in patients with advanced gastric cancer

目的观察晚期胃癌癌组织中切除修复交叉互补基因2（ERCC2）及P53蛋白表达状况及其与铂类方案化疗疗效及预后之间的关系。方法 56例患者静脉注射奥沙利铂135 mg·m-2,顺铂75 mg·m-2,共进行2~4周期化疗。用免疫组织化学方法检测晚期胃癌癌组织中ERCC2和P53蛋白的表达状况,评价化疗疗效及无进展生存期和总生存期。结果 ERCC2及P53表达与铂类化疗疗效有关（P〈0.05）。ERCC2及P53阳性总生存期较阴性者延长（P〈0.05）,P53阳性无进展生存期延长（P〈0.05）。结论 ERCC2及P53阳性表达与胃癌患者含铂类药物化疗疗效有相关。

Objective To investigate the expression of the excision repair cross complementing 2（ ERCC2） and P53 in the tissue of advanced liver cancer,and the relationship between the expression and the scheme with platinum chemotherapy curative effect and prognosis. Methods A total of 56 cancer patients were given oxaliplatin 135 mg·m- 2and cisplatin 75 mg·m- 2for treatment of 2- 4 recycle. Use the immunohistochemistry to detect the expression of the ERCC2 and P53 in the tissue of advanced liver cancer,give a platinum- based drugs chemotherapy,and then evaluate the chemotherapeutic effect,progression- free survival time and overall survival time. Results The expression of ERCC2 and P53 was associated with curative effect of platinum chemotherapy（ P〈0. 05）. The overall survival time of patients with positive expression of ERCC2 and P53 was longer than that of patients with the negative expression（ P〈0. 05）,and the progression- free survival time of patients with P53 positives was extended（ P〈0. 05）. Conclusion The expression of the ERCC2 and P53 was associated with the curative effect of platinum chemotherapy in the gastric carcinoma patients,which can be used as a detection index to evaluate the prognosis of the gastric cancer by chemotherapy.